These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 15544130)

  • 21. [Lower LDL and/or raise HDL. In what direction is lipidology moving?].
    Parhofer KG
    MMW Fortschr Med; 2007 May; 149(22):27. PubMed ID: 18069222
    [No Abstract]   [Full Text] [Related]  

  • 22. [Coronary disease patient has already LDL of 100 mg/dl. Why lipid lowering is still worthwhile].
    MMW Fortschr Med; 2005 Mar; 147(12):4. PubMed ID: 15832778
    [No Abstract]   [Full Text] [Related]  

  • 23. [Statin and absorption inhibitor work synergistically. More risk patient reach LDL cholesterol goal value].
    MMW Fortschr Med; 2007 Apr; 149(17):56-7. PubMed ID: 17674912
    [No Abstract]   [Full Text] [Related]  

  • 24. [Risk patients are often insufficiently treated. LDL cholesterol to be held down even more vigorously].
    MMW Fortschr Med; 2004 Oct; 146(44):56-7. PubMed ID: 15566253
    [No Abstract]   [Full Text] [Related]  

  • 25. [Lowering of LDL cholesterol prevents cardiovascular diseases. "Normal values" are too high--treatment time is a crucial factor].
    Rudling M
    Lakartidningen; 2006 Oct 25-31; 103(43):3278-82. PubMed ID: 17117659
    [No Abstract]   [Full Text] [Related]  

  • 26. Rationale for targeting multiple lipid pathways for optimal cardiovascular risk reduction.
    Ballantyne CM
    Am J Cardiol; 2005 Nov; 96(9A):14K-19K; discussion 34K-35K. PubMed ID: 16291009
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [For my coronary heart disease patients I strive for a 70 mg/dl LDL level (interview by Dr. med. Dirk Einecke)].
    Bode C
    MMW Fortschr Med; 2005 Jun; 147(23):49. PubMed ID: 15981909
    [No Abstract]   [Full Text] [Related]  

  • 28. [Type 2 diabetics are high risk patients. Concerning LDL-cholesterol to approach effectively to two sources].
    MMW Fortschr Med; 2005 Nov; 147(44):52-3. PubMed ID: 16302495
    [No Abstract]   [Full Text] [Related]  

  • 29. [Statin cuts cardiovascular risk in half].
    Einecke D
    MMW Fortschr Med; 2008 Dec; 150(49-50):12-3. PubMed ID: 19133364
    [No Abstract]   [Full Text] [Related]  

  • 30. [Lowering LDL cholesterol frequently does not adhere to guidelines. Also regard intestinal cholesterol source].
    MMW Fortschr Med; 2005 Jun; 147(23):48-9. PubMed ID: 15981908
    [No Abstract]   [Full Text] [Related]  

  • 31. Drug insight: the role of statins in combination with ezetimibe to lower LDL cholesterol.
    Gotto AM; Farmer JA
    Nat Clin Pract Cardiovasc Med; 2006 Dec; 3(12):664-72. PubMed ID: 17122799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease.
    Farnier M; Volpe M; Massaad R; Davies MJ; Allen C
    Int J Cardiol; 2005 Jul; 102(2):327-32. PubMed ID: 15982505
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association between LDL-cholesterol, statin therapy, physical activity and inflammatory markers in patients with stable coronary heart disease.
    König D; Deibert P; Winkler K; Berg A
    Exerc Immunol Rev; 2005; 11():97-107. PubMed ID: 16385847
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of statin use in patients with acute coronary syndromes and a serum low-density lipoproteinTsai TT; Nallamothu BK; Mukherjee D; Rubenfire M; Fang J; Chan P; Kline-Rogers E; Patel A; Armstrong DF; Eagle KA; Goldberg AD
    Am J Cardiol; 2005 Dec; 96(11):1491-3. PubMed ID: 16310427
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Coronary heart disease patient after myocardial infarct. Must LDL cholesterol now be reduced to 70 mg/dl?]].
    MMW Fortschr Med; 2005 Dec; 147(49-50):17-8. PubMed ID: 16401004
    [No Abstract]   [Full Text] [Related]  

  • 36. The inhibitory potency of clopidogrel on ADP-induced platelet activation is not attenuated when it is co-administered with atorvastatin (20 mg/day) for 5 weeks in patients with acute coronary syndromes.
    Mitsios JV; Papathanasiou AI; Elisaf M; Goudevenos JA; Tselepis AD
    Platelets; 2005 Aug; 16(5):287-92. PubMed ID: 16011979
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Plant stanoles in the prevention of cardiovascular diseases. Requirements regarding hard terminal points of soft margarines].
    Astrup AV; Ovesen LF; Stender S
    Ugeskr Laeger; 2001 Nov; 163(46):6437-9. PubMed ID: 11816923
    [No Abstract]   [Full Text] [Related]  

  • 38. [CARDS confirms usefulness of LDL lowering in type 2 diabetics].
    Bern VH
    Praxis (Bern 1994); 2004 Oct; 93(44):1 p following 1830. PubMed ID: 15559908
    [No Abstract]   [Full Text] [Related]  

  • 39. [Considerable LDL lowering is advantageous].
    MMW Fortschr Med; 2005 Sep; 147(35-36):9. PubMed ID: 16180563
    [No Abstract]   [Full Text] [Related]  

  • 40. Intensive lipid lowering with atorvastatin in coronary disease.
    Modest GA
    N Engl J Med; 2005 Jul; 353(1):93-6; author reply 93-6. PubMed ID: 16003833
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.